Bacillus Calmette-Guérin Manufacturing and SWOG S1602 Intergroup Clinical Trial

Journal of Urology

Volumn 197, Issue 3, 2017, Pages 538-540

  Meeks, Joshua J ^a   Lerner, Seth P ^b   Svatek, Robert S ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; TUBERCULIN; IMMUNOLOGICAL ADJUVANT;

ADAPTIVE IMMUNITY; BACTERIAL STRAIN; BIOLOGICAL MODEL; BLADDER CANCER; BLADDER PAPILLOMA; CANCER RECURRENCE; CANCER RISK; CARCINOMA IN SITU; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CYSTECTOMY; DRUG CONTAMINATION; DRUG MANUFACTURE; EDITORIAL; HIGH RISK POPULATION; HUMAN; LARGE SCALE PRODUCTION; MAINTENANCE THERAPY; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPIC VARIATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RECURRENCE RISK; STRAIN DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TUMOR IMMUNITY; VACCINE IMMUNOGENICITY; VIRUS CULTURE; BLADDER TUMOR; FOOD AND DRUG ADMINISTRATION; INTRAVESICAL DRUG ADMINISTRATION; SUPPLY AND DISTRIBUTION; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; URINARY BLADDER NEOPLASMS;

EID: 85010470344     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.12.024     Document Type: Editorial

References (19)

1. 1 Behr, M.A., Small, P.M., A historical and molecular phylogeny of BCG strains. Vaccine, 17, 1999, 915.
2. 2 Abdallah, A.M., Hill-Cawthorne, G.A., Otto, T.D., et al. Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations. Sci Rep, 5, 2015, 15443.
3. 3 Behr, M.A., Wilson, M.A., Gill, W.P., et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science, 284, 1999, 1520.
4. 4 Zhang, W., Zhang, Y., Zheng, H., et al. Genome sequencing and analysis of BCG vaccine strains. PLoS One, 8, 2013, e71243.
5. 5 Ritz, N., Hanekom, W.A., Robins-Browne, R., et al. Influence of BCG vaccine strain on the immune response and protection against tuberculosis. FEMS Microbiol Rev, 32, 2008, 821.
6. 6 Abate, G., Hoft, D.F., Variations between bacillus Calmette-Guerin strains: lessons from tuberculosis prevention. Eur Urol, 66, 2014, 692.
7. 7 Boehm, B., Cornell, J., Liss, M., et al. A network meta-analysis of intravesical BCG substrain efficacy in the treatment of non-muscle invasive bladder cancer. J Urol, suppl, 195, 2016, e327 abstract S&T-47.
8. 8 Sengiku, A., Ito, M., Miyazaki, Y., et al. A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol, 190, 2013, 50.
9. 9 Rentsch, C.A., Birkhauser, F.D., Biot, C., et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol, 66, 2014, 677.
10. 10 Witjes, J.A., Dalbagni, G., Karnes, R.J., et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. Urol Oncol, 34, 2016, 484.
11. 11 Lamm, D.L., Blumenstein, B.A., Crawford, E.D., et al. Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a Southwest Oncology Group study. Urol Oncol, 1, 1995, 119.
12. 12 Lamm, D.L., Blumenstein, B.A., Crawford, E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med, 325, 1991, 1205.
13. 13 Pinsky, C.M., Camacho, F.J., Kerr, D., et al. Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep, 69, 1985, 47.
14. 14 Malarkey, M.A., Warning Letter. Administration USFD, 2012, Public Health Service FDA, Rockville, Maryland.
15. 15 Veeratterapillay, R., Heer, R., Johnson, M.I., et al. High-risk non-muscle-invasive bladder cancer—therapy options during intravesical BCG shortage. Curr Urol Rep, 17, 2016, 68.
16. 16 Brausi, M., Morselli, S., The treatment of Ta-T1 bladder cancer in the era of worldwide BCG shortage. Minerva Urol Nefrol, 68, 2016, 192.
17. 17 Mostafid, A.H., Palou Redorta, J., Sylvester, R., et al. Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin. Eur Urol, 67, 2015, 359.
18. 18 Biot, C., Rentsch, C.A., Gsponer, J.R., et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med, 4, 2012, 137ra72.
19. 19 Jarow, J.P., Lerner, S.P., Kluetz, P.G., et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology, 83, 2014, 262.